Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAGHAV GOVINDARAJAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neuromuscular Medicine

NPI
1639481914
CMS profile
836879
Location
O FALLON, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$164,616.52

249 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ARGENX US, INC. $55,222.96 67
ABBVIE INC. $29,560.11 53
UCB, Inc. $24,062.97 48
Alexion Pharmaceuticals, Inc. $21,413.77 10
Janssen Scientific Affairs, LLC $16,870.00 8
Takeda Pharmaceuticals U.S.A., Inc. $9,761.18 13
Janssen Global Services, LLC $7,493.75 7
PFIZER INC. $175.44 40
Medtronic, Inc. $23.29 1
Novartis Pharmaceuticals Corporation $19.25 1
Baxter Healthcare $13.80 1

Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAGHAV GOVINDARAJAN

NPI 1639481914 · CMS profile ID 836879

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neuromuscular Medicine

O FALLON, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639481914?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAGHAV GOVINDARAJAN, NPI 1639481914, CMS profile ID 836879. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639481914?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RAGHAV GOVINDARAJAN, NPI 1639481914, CMS profile ID 836879. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639481914?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RAGHAV GOVINDARAJAN, NPI 1639481914, CMS profile ID 836879, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639481914?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

249 matching records · $164,616.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 249 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 249.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $8.2910/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050105899 CMS
ABBVIE INC. $25.3410/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374953 CMS
ARGENX US, INC. $9.7610/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434939 CMS
ABBVIE INC. $600.0010/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374949 CMS
ABBVIE INC. $3,000.0010/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374951 CMS
ARGENX US, INC. $3,450.0010/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434957 CMS
PFIZER INC. $3.1110/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050017849 CMS
UCB, Inc. $231.0010/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021629483 CMS
ABBVIE INC. $23.4110/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374947 CMS
ARGENX US, INC. $880.6010/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434961 CMS
ARGENX US, INC. $60.0010/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434965 CMS
ARGENX US, INC. $3,450.0010/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434969 CMS
ARGENX US, INC. $63.0210/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434983 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7,115.6310/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394627 CMS
UCB, Inc. $5.9110/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021643387 CMS
ARGENX US, INC. $60.0010/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434973 CMS
ARGENX US, INC. $904.4010/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434977 CMS
ARGENX US, INC. $68.4210/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434981 CMS
ABBVIE INC. $23.6610/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374945 CMS
ABBVIE INC. $33.4310/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374943 CMS
ARGENX US, INC. $51.3909/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434995 CMS
ARGENX US, INC. $24.7009/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434999 CMS
ARGENX US, INC. $77.0809/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060435003 CMS
ARGENX US, INC. $189.5109/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060435007 CMS
ARGENX US, INC. $256.6509/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060435009 CMS
ARGENX US, INC. $974.7009/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434987 CMS
ARGENX US, INC. $336.2409/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434991 CMS
ARGENX US, INC. $195.2909/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060435013 CMS
ABBVIE INC. $32.2109/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374941 CMS
Takeda Pharmaceuticals U.S.A., Inc. $464.0609/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394625 CMS
PFIZER INC. $4.1409/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049832457 CMS
UCB, Inc. $825.0009/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021629531 CMS
Takeda Pharmaceuticals U.S.A., Inc. $189.5509/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394623 CMS
UCB, Inc. $7.0909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021629379 CMS
Takeda Pharmaceuticals U.S.A., Inc. $225.4209/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394611 CMS
Takeda Pharmaceuticals U.S.A., Inc. $183.6009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394613 CMS
Takeda Pharmaceuticals U.S.A., Inc. $835.7409/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394615 CMS
Takeda Pharmaceuticals U.S.A., Inc. $561.9909/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394617 CMS
Takeda Pharmaceuticals U.S.A., Inc. $125.0009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394619 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.9409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055394621 CMS
ABBVIE INC. $7.5709/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374937 CMS
ABBVIE INC. $5.2509/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374939 CMS
Alexion Pharmaceuticals, Inc. $2,950.0009/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017005261 CMS
ABBVIE INC. $11.3809/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374935 CMS
ARGENX US, INC. $3,450.0009/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434921 CMS
ABBVIE INC. $11.3709/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374933 CMS
ARGENX US, INC. $575.0009/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060434949 CMS
Janssen Scientific Affairs, LLC $1,485.0009/01/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988574591 CMS
ABBVIE INC. $7.4508/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374931 CMS
ABBVIE INC. $8.5708/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997374929 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $80,547.89 86
PY2020 $58,037.52 51
PY2021 $114,197.83 92
PY2022 $92,984.71 101
PY2023 $164,616.52 249
PY2024 $149,709.19 197
PY2025 $211,072.04 256

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,212,522.78 28
PY2024 Principal investigator $254,362.00 38
PY2023 Principal investigator $90,342.68 72
PY2022 Principal investigator $65,318.88 11
PY2021 Principal investigator $123,245.54 27
PY2020 Principal investigator $132,009.54 34
PY2019 Recipient $31,253.74 6
PY2019 Principal investigator $63,438.60 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $1,000.00 12/22/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237155975
Principal investigator 1 ARGENX US, INC. $10,000.00 12/19/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237155951
Principal investigator 1 ARGENX US, INC. $2,475.00 12/19/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis No dispute reported 06/30/2026 1237155956
Principal investigator 1 Janssen Research & Development, LLC $21,000.00 12/11/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOP
Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab No dispute reported 06/30/2026 1175360905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $234.00 11/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184265783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $63.70 11/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184265785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $283.40 11/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184265787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.90 11/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184265789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $234.00 11/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184265791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.30 11/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184265793
Principal investigator 1 ARGENX US, INC. $1,127.28 11/12/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237155971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $234.00 10/30/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184256141
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,500.00 10/22/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care No dispute reported 06/30/2026 1223287159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,303.65 08/28/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184231711
Principal investigator 1 ARGENX US, INC. $563.64 08/13/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237155967
Principal investigator 1 Alexion Pharmaceuticals, Inc. $9,356.60 07/25/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1185553361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $925.74 05/29/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184200223
Principal investigator 1 ARGENX US, INC. $3,655.08 05/28/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237155960
Principal investigator 1 ARGENX US, INC. $5,000.00 05/28/2025 Non-covered Recipient Entity
Prairie Ed and Research Cooperative and HSHS Medical Group
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa No dispute reported 06/30/2026 1237155964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $128.70 04/09/2025 Non-covered Recipient Entity
PRAIRIEEDUCATIONRESEARCHCOOPERATIVEPERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184182228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $935.10 03/24/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184178722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,231.46 02/19/2025 Non-covered Recipient Entity
PRAIRIEEDUCATIONRESEARCHCOOPERATIVEPERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $925.74 02/19/2025 Non-covered Recipient Entity
PRAIRIEEDUCATIONRESEARCHCOOPERATIVEPERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154708
Principal investigator 1 UCB SA $8,315.80 01/27/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION & RESEARCH COOPERATIVE PERC
A PHASE 3B, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ZILUCOPLAN IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS SWITCHING FROM INTRAVENOUS COMPLEMENT COMPONENT 5 INHIBITORS TO SUBCUTANEOUS ZILUCOPLAN No dispute reported 06/30/2026 1246658296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.80 01/02/2025 Non-covered Recipient Entity
PRAIRIEEDUCATIONRESEARCHCOOPERATIVEPERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184144382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.40 01/02/2025 Non-covered Recipient Entity
PRAIRIEEDUCATIONRESEARCHCOOPERATIVEPERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184144384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/02/2025 Non-covered Recipient Entity
PRAIRIEEDUCATIONRESEARCHCOOPERATIVEPERC
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184144386
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,134,630.49 01/01/2025 Non-covered Recipient Entity
PRAIRIE EDUCATION AND RESEARCH COOPERATIVE
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190304547